Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistBased on limited metadata from this January 2018 FDA Warning Letter, Opiate Freedom Center received enforcement action, though the specific subject matter and detailed violations are not available in the provided information. The letter was classified under "Other" product type, suggesting the violations may not fall under traditional drug or device categories. Without access to the full letter text or specific issuing office designation, the exact nature of the regulatory concerns and the FDA's specific enforcement basis cannot be determined from this summary data alone.